文献速递艾滋病与性传播感染

阿扎那韦胞内浓度在妊娠期保持稳定

Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

结果显示阿扎那韦细胞内浓度及细胞内/血浆比值随时间无显著变化(P > 0.05),支持全程使用标准300/100 mg剂量。

要点

  • 阿扎那韦细胞内浓度在妊娠各期及产后无显著变化(P > 0.05)。
  • 细胞内/血浆比值各期分别为1.32、1.34、1.38和1.07,变化无统计学意义。
  • 结果支持妊娠全程维持阿扎那韦/利托那韦300/100 mg标准剂量。

核心结论

  • 阿扎那韦细胞内暴露在妊娠期间保持不变,支持妊娠全程使用标准300/100 mg阿扎那韦/利托那韦剂量。

研究设计与样本

  • 在妊娠早、中、晚期及产后各访视点测定血浆和细胞内阿扎那韦与利托那韦谷浓度(给药后24 ± 3 h)。
  • 采用经验证的HPLC-MS和HPLC-光电二极管阵列方法测定,并直接评估细胞体积。

主要发现

  • 基线中位年龄32岁(27-35),所有患者血浆HIV RNA <50 copies/mL,中位CD4+计数736 cells/mm3(542-779)。
  • 阿扎那韦血浆浓度在妊娠早、中、晚期及产后分别为441 ng/mL(261-1557)、710 ng/mL(338-1085)、556 ng/mL(334-1022)和837 ng/mL(608-1757)。
  • 阿扎那韦细胞内浓度分别为743 ng/mL(610-1928)、808 ng/mL(569-1620)、756 ng/mL(384-1074)和706 ng/mL(467-2688)。
  • 阿扎那韦细胞内/血浆比值分别为1.32(0.98-2.77)、1.34(1.13-1.88)、1.38(0.61-2.63)和1.07(0.56-2.69)。
  • 阿扎那韦细胞内浓度及细胞内/血浆比值随时间变化无统计学意义(P > 0.05)。

关键数值与推荐

  • 阿扎那韦细胞内浓度及细胞内/血浆比值随时间变化无统计学意义(P > 0.05)。
  • 阿扎那韦血浆浓度在妊娠早、中、晚期及产后分别为441、710、556和837 ng/mL(中位数,IQR见原文)。

临床怎么用

  • 妊娠期HIV感染者可维持阿扎那韦/利托那韦300/100 mg标准剂量,无需因妊娠调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atazanavir (300 mg) boosted by ritonavir (100 mg) is the preferred third drug in pregnancy. However, there is still discordance on atazanavir dose increase during the third trimester. OBJECTIVES: To evaluate plasma and intracellular atazanavir and ritonavir concentrations in HIV-infected women during pregnancy and after delivery. METHODS: This was an observational study. HIV-infected pregnant patients treated with atazanavir/ritonavir plus either tenofovir/emtricitabine or abacavir/lamivudine had been prospectively enrolled after having signed a written informed consent form. Plasma and intracellular atazanavir and ritonavir Ctrough (24 ± 3 h after drug intake) were measured at each visit during the first, second and third trimesters and post-partum using validated HPLC-MS and HPLC-photodiode array methods (with direct evaluation of cellular volume). Data are described as median (IQR) and compared through non-parametric tests. RESULTS: Twenty-five patients were enrolled; at baseline, the median age was 32 years (27-35). All patients had plasma HIV RNA <50 copies/mL; the median CD4+ count was 736 cells/mm3 (542-779). Atazanavir plasma concentrations were 441 ng/mL (261-1557), 710 ng/mL (338-1085), 556 ng/mL (334-1022) and 837 ng/mL (608-1757) during the first, second and third trimesters and post-partum, respectively; intracellular concentrations were 743 ng/mL (610-1928), 808 ng/mL (569-1620), 756 ng/mL (384-1074) and 706 ng/mL (467-2688), respectively. Atazanavir intracellular/plasma ratios were 1.32 (0.98-2.77), 1.34 (1.13-1.88), 1.38 (0.61-2.63) and 1.07 (0.56-2.69), respectively. Atazanavir intracellular concentrations and intracellular/plasma ratios showed non-significant changes over time (P > 0.05). CONCLUSIONS: This is the first demonstration that intracellular atazanavir exposure remains unchanged during pregnancy supporting the standard 300/100 mg atazanavir/ritonavir dosing throughout pregnancy.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Focà E, Calcagno A, Bonito A, et al. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. J Antimicrob Chemother. 2017. PMID: 28961777. doi:10.1093/jac/dkx274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。